Author:
Hosokawa Kazuya,Ohnishi-Wada Tomoko,Sameshima-Kaneko Hisayo,Nagasato Tomoka,Miura Naoki,Kikuchi Kiyoshi,Koide Takehiko,Maruyama Ikuro,Urano Tetsumei
Reference31 articles.
1. Tissue plasminogen activator for acute ischemic stroke;The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group;N. Engl. J. Med.,1995
2. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials;Lees;Lancet,2010
3. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III trial;de Los Rios la Rosa;Stroke,2012
4. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study;Morange;Arterioscler. Thromb. Vasc. Biol.,2007
5. Plasminogen activator inhibitor-1 levels and polymorphisms;Francis;Arch. Pathol. Lab. Med.,2002
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献